secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178978
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025
----------------------------------------------------------------------

- Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.
- Q2 net loss $15.4M ($1.14/sh) vs $14.1M ($44.82/sh) YoY; R&D spend rose to $12.6M.
- Completed enrollment in monotherapy and fulvestrant combo arms; data from both due Q4 2025.
- New triplet arm initiated: OKI-219 + fulvestrant + ribociclib in HR+ metastatic breast cancer.
- New triplet arm: OKI-219 + trastuzumab + tucatinib in HER2+ breast cancer; pan-mutant candidate nomination by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312525178978/0001193125-25-178978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312525178978/okur-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer